About Haleon plc
https://www.haleon.comHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
CEO
Claire Dickson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 38
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DODGE & COX
Shares:154.38M
Value:$1.54B
FMR LLC
Shares:104M
Value:$1.03B
CLEARBRIDGE INVESTMENTS, LLC
Shares:33.35M
Value:$331.81M
Summary
Showing Top 3 of 694
About Haleon plc
https://www.haleon.comHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $5.48B | $2.33B | $806M | 14.71% | $0.18 | $1.39B |
| Q2-2025 | $5.48B ▲ | $2.33B ▲ | $806M ▲ | 14.71% | $0.18 ▲ | $1.39B ▲ |
| Q1-2025 | $2.74B ▼ | $1.17B ▼ | $403M ▼ | 14.71% ▲ | $0.09 ▼ | $667M ▼ |
| Q4-2024 | $5.54B ▲ | $2.35B ▲ | $716M ▲ | 12.93% ▼ | $0.16 ▲ | $1.26B ▲ |
| Q3-2024 | $2.78B | $1.04B | $485M | 17.45% | $0.11 | $716M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $676M | $31.83B | $15.83B | $15.94B |
| Q1-2025 | $676M ▼ | $31.83B ▼ | $15.83B ▼ | $15.94B ▼ |
| Q4-2024 | $2.25B ▲ | $34.31B ▲ | $18.09B ▲ | $16.17B ▼ |
| Q3-2024 | $531M | $0 ▼ | $-16.71B ▼ | $16.71B ▲ |
| Q2-2024 | $531M | $33.4B | $16.69B | $16.6B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $806M | $1.03B | $-76M | $-2.52B | $0 | $931M |
| Q2-2025 | $806M ▲ | $1.03B ▲ | $-76M ▼ | $-2.52B ▼ | $0 | $931M ▲ |
| Q1-2025 | $403M ▼ | $513.5M ▲ | $-38M ▼ | $-1.26B ▼ | $0 | $465.5M ▲ |
| Q4-2024 | $716M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $485M | $0 | $0 | $0 | $0 | $0 |
Revenue by Products
| Product | Q2-2023 |
|---|---|
 Respiratory Health | $840.00M ▲ |
CEO
Claire Dickson
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 38
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DODGE & COX
Shares:154.38M
Value:$1.54B
FMR LLC
Shares:104M
Value:$1.03B
CLEARBRIDGE INVESTMENTS, LLC
Shares:33.35M
Value:$331.81M
Summary
Showing Top 3 of 694